Arie Van Tol

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10742503/publications.pdf

Version: 2024-02-01

159585 138484 3,310 60 30 58 citations h-index g-index papers 61 61 61 2130 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Elevated expression of PLTP is atherogenic in apolipoprotein E deficient mice. Atherosclerosis, 2013, 227, 37-42.	0.8	7
2	Carotid intima media thickness is related positively to plasma pre ß-high density lipoproteins in non-diabetic subjects. Clinica Chimica Acta, 2012, 413, 473-477.	1.1	18
3	Cholesteryl Ester Transfer Protein Inhibition in Cardiovascular Risk Management: Ongoing Trials will End the Confusion. Cardiovascular Therapeutics, 2011, 29, e89-e99.	2.5	28
4	Plasma Cholesteryl Ester Transfer, But Not Cholesterol Esterification, Is Related to Lipoprotein-Associated Phospholipase A2: Possible Contribution to an Atherogenic Lipoprotein Profile. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1077-1084.	3.6	16
5	Genetic Variation at the <i>Phospholipid Transfer Protein</i> Locus Affects Its Activity and High-Density Lipoprotein Size and Is a Novel Marker of Cardiovascular Disease Susceptibility. Circulation, 2010, 122, 470-477.	1.6	86
6	Reduction of HDL levels lowers plasma PLTP and affects its distribution among lipoproteins in mice. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2009, 1791, 790-796.	2.4	6
7	Novel roles of hepatic lipase and phospholipid transfer protein in VLDL as well as HDL metabolism. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2009, 1791, 1031-1036.	2.4	17
8	Elevation of systemic PLTP, but not macrophage-PLTP, impairs macrophage reverse cholesterol transport in transgenic mice. Atherosclerosis, 2009, 204, 429-434.	0.8	37
9	Derangements of intravascular remodeling of lipoproteins in type 2 diabetes mellitus: Consequences for atherosclerosis development. Current Diabetes Reports, 2008, 8, 65-70.	4.2	8
10	Phospholipid transfer protein activity is determined by typeÂ2 diabetes mellitus and metabolic syndrome, and is positively associated with serum transaminases. Clinical Endocrinology, 2008, 68, 375-381.	2.4	22
11	Fibroblast cholesterol efflux to plasma from metabolic syndrome subjects is not defective despite low high-density lipoprotein cholesterol. European Journal of Endocrinology, 2008, 158, 53-60.	3.7	32
12	Acute Elevation of Plasma PLTP Activity Strongly Increases Pre-existing Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 1277-1282.	2.4	28
13	Plasma phospholipid transfer activity is essential for increased atherogenesis in PLTP transgenic mice: a mutation-inactivation study. Journal of Lipid Research, 2008, 49, 2504-2512.	4.2	15
14	Plasma Lecithin: Cholesterol Acyltransferase Activity Is Elevated in Metabolic Syndrome and Is an Independent Marker of Increased Carotid Artery Intima Media Thickness. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4860-4866.	3.6	54
15	Evaluation of phospholipid transfer protein as a therapeutic target. Future Lipidology, 2008, 3, 327-335.	0.5	9
16	Elevated Expression of Phospholipid Transfer Protein in Bone Marrow Derived Cells Causes Atherosclerosis. PLoS ONE, 2008, 3, e2255.	2.5	23
17	Cholesteryl ester transfer protein and hyperalphalipoproteinemia in Caucasians. Journal of Lipid Research, 2007, 48, 674-682.	4.2	30
18	High plasma cholesteryl ester transfer protein levels may favour reduced incidence of cardiovascular events in men with low triglycerides. European Heart Journal, 2007, 28, 1012-1018.	2.2	68

#	Article	IF	CITATIONS
19	Concerted actions of cholesteryl ester transfer protein and phospholipid transfer protein in type 2 diabetes: effects of apolipoproteins. Current Opinion in Lipidology, 2007, 18, 251-257.	2.7	47
20	Atherogenic, enlarged, and dysfunctional HDL in human PLTP/apoA-I double transgenic mice. Journal of Lipid Research, 2007, 48, 2622-2631.	4.2	22
21	Plasma phospholipid transfer protein activity, a determinant of HDL kinetics in vivo. Clinical Endocrinology, 2007, 67, 316-317.	2.4	1
22	Inducible expression of phospholipid transfer protein (PLTP) in transgenic mice: acute effects of PLTP on lipoprotein metabolism. Transgenic Research, 2007, 16, 503-513.	2.4	6
23	Sex differences in atherosclerosis in mice with elevated phospholipid transfer protein activity are related to decreased plasma high density lipoproteins and not to increased production of triglycerides. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2006, 1761, 1070-1077.	2.4	9
24	Cellular cholesterol efflux to plasma from proteinuric patients is elevated and remains unaffected by antiproteinuric treatment. Nephrology Dialysis Transplantation, 2006, 21, 101-106.	0.7	9
25	An Increased Coronary Risk Is Paradoxically Associated with Common Cholesteryl Ester Transfer Protein Gene Variations That Relate to Higher High-Density Lipoprotein Cholesterol: A Population-Based Study. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3382-3388.	3.6	115
26	Plasma Phospholipid Transfer Protein Activity Is Decreased in Type 2 Diabetes During Treatment With Atorvastatin: A Role for Apolipoprotein E?. Diabetes, 2006, 55, 1491-1496.	0.6	24
27	The Effect of Cholesteryl Ester Transfer Protein â~629C→A Promoter Polymorphism on High-Density Lipoprotein Cholesterol Is Dependent on Serum Triglycerides. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4198-4204.	3.6	67
28	Plasma Cholesteryl Ester Transfer Is a Determinant of Intima-Media Thickness in Type 2 Diabetic and Nondiabetic Subjects: Role of CETP and Triglycerides. Diabetes, 2005, 54, 3554-3559.	0.6	76
29	Fenofibrate reverses the decline in HDL cholesterol in mice overexpressing human phospholipid transfer protein. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2005, 1738, 48-53.	2.4	9
30	Elevation of plasma phospholipid transfer protein increases the risk of atherosclerosis despite lower apolipoprotein B-containing lipoproteins. Journal of Lipid Research, 2004, 45, 805-811.	4.2	44
31	CETP gene variation: relation to lipid parameters and cardiovascular risk. Current Opinion in Lipidology, 2004, 15, 393-398.	2.7	59
32	Abnormal Phospholipid Composition Impairs HDL Biogenesis and Maturation in Mice Lacking Abca1â€. Biochemistry, 2003, 42, 8569-8578.	2.5	39
33	Common Cholesteryl Ester Transfer Protein Gene Polymorphisms and the Effect of Atorvastatin Therapy in Type 2 Diabetes. Diabetes Care, 2003, 26, 1216-1223.	8.6	102
34	Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG. Journal of Lipid Research, 2003, 44, 1462-1469.	4.2	37
35	Increased Fecal Bile Acid Excretion in Transgenic Mice With Elevated Expression of Human Phospholipid Transfer Protein. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 892-897.	2.4	56
36	Phospholipid transfer protein and atherosclerosis. Advances in Molecular and Cell Biology, 2003, 33, 531-541.	0.1	0

#	Article	IF	Citations
37	Increased Risk of Atherosclerosis by Elevated Plasma Levels of Phospholipid Transfer Protein. Journal of Biological Chemistry, 2002, 277, 48938-48943.	3.4	113
38	Elevation of plasma phospholipid transfer protein in transgenic mice increases VLDL secretion. Journal of Lipid Research, 2002, 43, 1875-1880.	4.2	77
39	Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans. Circulation, 2002, 105, 2159-2165.	1.6	441
40	Cholesteryl ester flux from HDL to VLDL-1 is preferentially enhanced in type IIB hyperlipidemia in the postprandial state. Journal of Lipid Research, 2002, 43, 1652-1660.	4.2	54
41	Phospholipid transfer protein. Current Opinion in Lipidology, 2002, 13, 135-139.	2.7	107
42	Kinetics of HDL Cholesterol and Paraoxonase Activity in Moderate Alcohol Consumers. Alcoholism: Clinical and Experimental Research, 2002, 26, 1430-1435.	2.4	76
43	Kinetics of HDL Cholesterol and Paraoxonase Activity in Moderate Alcohol Consumers. Alcoholism: Clinical and Experimental Research, 2002, 26, 1430-1435.	2.4	15
44	Relationship of Phospholipid Transfer Protein Activity to HDL and Apolipoprotein B-Containing Lipoproteins in Subjects With and Without Type 1 Diabetes. Diabetes, 2002, 51, 3300-3305.	0.6	63
45	Apolipoprotein A-II/A-I Ratio Is a Key Determinant in Vivo of HDL Concentration and Formation of Pre-β HDL Containing Apolipoprotein A-II. Biochemistry, 2001, 40, 12243-12253.	2.5	27
46	Moderate alcohol consumption: effects on lipids and cardiovascular disease risk. Current Opinion in Lipidology, 2001, 12, 19-23.	2.7	71
47	Evaluation of phospholipid transfer protein and cholesteryl ester transfer protein as contributors to the generation of prel²-high-density lipoproteins. Biochemical Journal, 2001, 360, 379.	3.7	27
48	Evaluation of phospholipid transfer protein and cholesteryl ester transfer protein as contributors to the generation of prel²-high-density lipoproteins. Biochemical Journal, 2001, 360, 379-385.	3.7	41
49	Proatherogenic Role of Elevated CE Transfer From HDL to VLDL ₁ and Dense LDL in Type 2 Diabetes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 282-288.	2.4	224
50	Human Plasma Phospholipid Transfer Protein Increases the Antiatherogenic Potential of High Density Lipoproteins in Transgenic Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1082-1088.	2.4	188
51	Moderate Alcohol Consumption and Changes in Postprandial Lipoproteins of Premenopausal and Postmenopausal Women: A Diet-Controlled, Randomized Intervention Study. Journal of Women's Health and Gender-Based Medicine, 2000, 9, 607-616.	1.5	31
52	Low plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone deficient and acromegalic men: role in altered high density lipoproteins. Atherosclerosis, 2000, 153, 491-498.	0.8	26
53	Effect of growth hormone replacement therapy on plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone-deficient adults. Journal of Lipid Research, 2000, 41, 925-932.	4.2	20
54	Daily moderate alcohol consumption increases serum paraoxonase activity; a diet-controlled, randomised intervention study in middle-aged men. Atherosclerosis, 1999, 147, 405-410.	0.8	179

#	Article	IF	CITATION
55	Elevated plasma cholesteryl ester transfer in NIDDM: relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein. Atherosclerosis, 1998, 140, 71-79.	0.8	118
56	Lipoprotein phospholipid composition and LCAT activity in nephrotic and analbuminemic rats. Kidney International, 1994, 46, 97-104.	5.2	30
57	Hepatic lipase and lipoprotein lipase are not major determinants of the low density lipoprotein subclass pattern in human subjects with coronary heart disease. Atherosclerosis, 1994, 107, 45-54.	0.8	79
58	Excessive Cholesterolemic Response in Analbuminemic Rats Fed a Cholesterol-Rich Diet Containing Casein. Journal of Nutrition, 1992, 122, 520-527.	2.9	10
59	Discrepancies in the catabolic pathways of human and rat high-density lipoprotein apolipoprotein A-I in the rat. European Journal of Clinical Investigation, 1985, 15, 395-402.	3.4	6
60	Turnover and uptake by organs of radioactive serum high-density lipoprotein cholesteryl esters and phospholipids in the rat in vivo. Biochemical Journal, 1981, 196, 877-885.	3.7	61